Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis

Background Cardiac hypertrophy and fibrosis are common adaptive responses to injury and stress, eventually leading to heart failure. Hypoxia signaling is important to the (patho)physiological process of cardiac remodeling. However, the role of endothelial PHD2 (prolyl‐4 hydroxylase 2)/hypoxia inducible factor (HIF) signaling in the pathogenesis of cardiac hypertrophy and heart failure remains elusive. Methods and Results Mice with Egln1Tie2Cre (Tie2‐Cre‐mediated deletion of Egln1 [encoding PHD2]) exhibited left ventricular hypertrophy evident by increased thickness of anterior and posterior wall and left ventricular mass, as well as cardiac fibrosis. Tamoxifen‐induced endothelial Egln1 deletion in adult mice also induced left ventricular hypertrophy and fibrosis. Additionally, we observed a marked decrease of PHD2 expression in heart tissues and cardiovascular endothelial cells from patients with cardiomyopathy. Moreover, genetic ablation of Hif2a but not Hif1a in Egln1Tie2Cre mice normalized cardiac size and function. RNA sequencing analysis also demonstrated HIF‐2α as a critical mediator of signaling related to cardiac hypertrophy and fibrosis. Pharmacological inhibition of HIF‐2α attenuated cardiac hypertrophy and fibrosis in Egln1Tie2Cre mice. Conclusions The present study defines for the first time an unexpected role of endothelial PHD2 deficiency in inducing cardiac hypertrophy and fibrosis in an HIF‐2α–dependent manner. PHD2 was markedly decreased in cardiovascular endothelial cells in patients with cardiomyopathy. Thus, targeting PHD2/HIF‐2α signaling may represent a novel therapeutic approach for the treatment of pathological cardiac hypertrophy and failure.

[1]  Dan Zhang,et al.  Construction of a human cell landscape at single-cell level , 2020, Nature.

[2]  C. Evans,et al.  Endothelial Hypoxia-Inducible Factor-1α Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through FoxM1. , 2019, The American journal of pathology.

[3]  C. Coarfa,et al.  Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction. , 2019, Circulation.

[4]  Hai Yan,et al.  Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure , 2019, JACC. Basic to translational science.

[5]  K. Schäfer,et al.  Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure , 2019, Front. Cardiovasc. Med..

[6]  R. Machado,et al.  Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF‐2&agr; Inhibitor , 2018, American journal of respiratory and critical care medicine.

[7]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[8]  You-yang Zhao,et al.  Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension , 2018, American journal of respiratory and critical care medicine.

[9]  V. Talman,et al.  Cardiomyocyte—Endothelial Cell Interactions in Cardiac Remodeling and Regeneration , 2018, Front. Cardiovasc. Med..

[10]  J. Sadoshima,et al.  Mechanisms of physiological and pathological cardiac hypertrophy , 2018, Nature Reviews Cardiology.

[11]  T. Jardetzky,et al.  Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus , 2017, Nature Microbiology.

[12]  J. Molkentin,et al.  Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. , 2017, The Journal of clinical investigation.

[13]  N. Bursac,et al.  The extracellular matrix protein agrin promotes heart regeneration in mice , 2017, Nature.

[14]  M. Wolf,et al.  FGF23/FGFR4-mediated left ventricular hypertrophy is reversible , 2017, Scientific Reports.

[15]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[16]  Hyejin Cho,et al.  On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models , 2016, Nature.

[17]  D. Srivastava,et al.  A Long Non-Coding RNA Defines an Epigenetic Checkpoint in Cardiac Hypertrophy , 2016, Nature Medicine.

[18]  G. Hasenfuss,et al.  Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice. , 2016, Cardiovascular research.

[19]  J. Wharton,et al.  Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2&agr; , 2016, Circulation.

[20]  M. Simon,et al.  SnapShot: Hypoxia-Inducible Factors , 2015, Cell.

[21]  D. Predescu,et al.  Endothelial &bgr;-Catenin Signaling Is Required for Maintaining Adult Blood–Brain Barrier Integrity and Central Nervous System Homeostasis , 2015, Circulation.

[22]  P. Ratcliffe,et al.  HIF hydroxylase pathways in cardiovascular physiology and medicine. , 2015, Circulation research.

[23]  M. Sperandio,et al.  Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin , 2015, Nature Communications.

[24]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[25]  A. Cohen-Solal,et al.  Galectin‐3 in heart failure with preserved ejection fraction , 2013, European journal of heart failure.

[26]  C. Tschöpe,et al.  Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? , 2013, Cardiovascular research.

[27]  X. Papademetris,et al.  NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. , 2013, The Journal of clinical investigation.

[28]  De-Li Dong,et al.  Bone Morphogenetic Protein-4 Mediates Cardiac Hypertrophy, Apoptosis, and Fibrosis in Experimentally Pathological Cardiac Hypertrophy , 2013, Hypertension.

[29]  D. Kass,et al.  Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling , 2012, Proceedings of the National Academy of Sciences.

[30]  G. Semenza,et al.  Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.

[31]  W. Wong,et al.  Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.

[32]  Howard Y. Chang,et al.  Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.

[33]  T. Golub,et al.  Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. , 2008, Molecular cell.

[34]  K. Miyazono,et al.  Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  J. Guan,et al.  Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK , 2008, The Journal of cell biology.

[36]  W. Kaelin,et al.  Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. , 2008, Blood.

[37]  P. Carmeliet,et al.  Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. , 2007, The Journal of clinical investigation.

[38]  K. Takeda,et al.  Prolyl Hydroxylase Domain 2 Protein Suppresses Hypoxia-Induced Endothelial Cell Proliferation , 2007, Hypertension.

[39]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[40]  Mark A. Hall,et al.  Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. , 2004, Blood.

[41]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[42]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[43]  P. O’Farrell.  Faculty Opinions recommendation of HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. , 2001 .

[44]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[45]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[46]  G. Hu,et al.  Endothelial Hypoxia-Inducible Factor-1a Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through Forkhead Box Protein M1 , 2019 .

[47]  Kai-Uwe Eckardt,et al.  The FASEB Journal express article 10.1096/fj.02-0445fje. Published online December 17, 2002. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs , 2022 .